Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination drug containing three active ingredients: - **Methylprednisolone** is a synthetic corticosteroid that suppresses inflammation and immune responses by modulating gene expression, reducing the production of inflammatory mediators, and inhibiting leukocyte infiltration. It is used to treat conditions such as severe allergies, asthma, autoimmune disorders, and certain cancers[1][5]. - **Paracetamol** (also known as acetaminophen) is an analgesic and antipyretic agent that reduces fever and relieves mild to moderate pain. Its mechanism involves inhibition of prostaglandin synthesis in the central nervous system. - **Dexchlorpheniramine** is a first-generation antihistamine that acts as an antagonist at histamine H1 receptors, providing relief from allergic symptoms like runny nose, sneezing, itching, and watery eyes[2][7]. The combination may be used for symptomatic relief in conditions involving inflammation or allergy with associated pain or fever.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylprednisolone + paracetamol + dexchlorpheniramine.